DTIL (Precision BioSciences) Moat Score: 5/10 (As of Jul. 11, 2026)


DTIL Precision BioSciences Inc DTIL
50 GF Score
Price $8.77
GF Value $1.83
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Precision BioSciences Moat Score?

Precision BioSciences DTIL -4.37% 50 Moat Score is 5 as of Jul. 11, 2026. GuruFocus rates DTIL with a GF Score™ of 50/100 and a GF Value™ of $1.83 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,395 Biotechnology companies, Precision BioSciences ranks better than 96.7% on this metric.

Precision BioSciences has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Precision BioSciences has Narrow Moat: DTIL has valuable intellectual property in gene editing and a solid R&D capability. However, it faces intense competition and lacks strong pricing power or significant customer switching costs, resulting in a solid but not wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Precision BioSciences might have Narrow Moat - Solid narrow moat.

Precision BioSciences  (NAS:DTIL) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Precision BioSciences Moat Score Related Terms

DTIL vs NBP, HUMA, ORMP: Moat Score Comparison

For the Biotechnology subindustry, Precision BioSciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Precision BioSciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precision BioSciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Precision BioSciences's Moat Score falls into.


DTIL
50GF Score
Precision BioSciences Inc DTIL
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Precision BioSciences (DTIL) has a Moat Score of 5 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Precision BioSciences ranks #46 out of 1395 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Precision BioSciences' Moat Score too high?
Precision BioSciences' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Precision BioSciences' value of 5 is 150% above this industry median. Based on the distribution chart, Precision BioSciences ranks #46 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Precision BioSciences has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' Moat Score compare to NBP and HUMA?
According to the Biotechnology industry distribution chart, Precision BioSciences ranks #46 out of 1395 companies for Moat Score. This places Precision BioSciences in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Precision BioSciences' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precision BioSciences's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precision BioSciences's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (DTIL) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $8.77 — trading 379% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Precision BioSciences' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Precision BioSciences (DTIL), the current Moat Score is 5 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precision BioSciences (DTIL) Overvalued in 2026?

Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued. The current stock price of $8.77 is trading 379% above its estimated GF Value™ of $1.83. GuruFocus considers Precision BioSciences to be Significantly Overvalued.

Key valuation signals for DTIL:

  • Moat Score: 5
  • GF Value™: $1.83 vs. price of $8.77 (379% above fair value)
  • GF Score™: 50/100 with 5 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1395)

No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precision BioSciences Business Description

Other Exchanges PBS0:Germany
Address 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
50GF Score

Get the complete analysis for DTIL

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.77
Price
$1.83
GF Value